SELLAS Life Sciences Group, Inc. (SLS) experiences a decrease of 7.53% in aftermarket. However, the last trading session concluded at $7.04 with an incline of 0.57%.
Third Quarter 2021 Results – What are the new updates?
SLS reported third-quarter 2021 results on 12th November 2021. According to the report, the cash and cash equivalents came out to be $26.3 million. Moreover, the third quarter of 2021 saw $2.4 million in general and administrative costs, $2.1 million more than in the same quarter of 2020.
Furthermore, the research and development costs were $4.5 million, $2.4 million more than the same quarter of 2020. There was no licensing income in the third quarter of 2021. This also includes revenue from the Company’s license agreement with 3D Medicines.
Second Quarter 2021 Results by SLS – Latest News
SLS announced second-quarter 2021 results on 12th August 2021. According to the announcements, the revenue licensing agreement was $1.9 million in the second quarter of 2021. Moreover, the second quarter of 2021 saw $3.5 million in research and development costs, $2.3 million more than the same time of 2020. Moreover, research and development costs totaled $7.7 million, $4.1 million more in the same period of 2020.
The increase was largely due to rising clinical trial costs associated with the Company’s Phase 3 REGAL GPS clinical study in AML patients. Last but not the least, the general and administrative costs were $2.8 million, $2.0 million more than the same period of 2020.
Data from Ongoing Phase 1/2 Study of Galinpepimut-S
On 30th June 2021, SLS updated about the clinical data and preliminary immunobiological results from its Phase 1/2 clinical study. Eleven patients were examined for clinical and immunological responses after receiving at least three GPS doses, the last of which was coupled with pembrolizumab.
Moreover, 66.7 percent of patients were resistant to or had failed second-line medicines. All of the patients were resistant to platinum-based treatment, which was the standard of care. Patients who get standard-of-care platinum-based treatment should expect an overall survival of nine to twelve months.
Because all patients are still alive at the time of the analysis, which is more than nine months, the median overall survival among the participants in this experiment is unknown.
